Zenas BioPharma Inc. Stock Price, News & Analysis

Zenas BioPharma (Nasdaq: ZBIO) announced management will present at two investor conferences: the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 11:00 a.m. GMT, and the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 7:55 a.m. ET.

Live webcasts and archived replays will be available under Events and Presentations in the company’s Investor & Media Relations website.

Zenas BioPharma (Nasdaq: ZBIO) announced positive Phase 2 MoonStone results for obexelimab in relapsing multiple sclerosis on October 27, 2025. Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium-enhancing T1 lesions versus placebo over weeks 8 and 12 (p=0.0009), with adjusted mean new GdE T1 lesions per scan of 0.01 vs 0.23. The drug also significantly reduced new/enlarging T2 lesions. Safety was consistent with prior trials, including infections and hypersensitivity, most commonly mild injection-site reactions. Zenas expects 24-week MoonStone data in Q1 2026 and additional toplines from INDIGO (IgG4-RD) and SunStone (SLE) in late 2025–mid 2026.

Zenas BioPharma (Nasdaq: ZBIO) announced a license agreement with InnoCare granting Zenas global MS and non-oncology rights to orelabrutinib plus rights to an oral IL-17AA/AF inhibitor and an oral, brain-penetrant TYK2 inhibitor. A global Phase 3 trial in PPMS has been initiated and a SPMS Phase 3 is expected to start in 1Q 2026. The two early candidates aim for IND/Phase 1 starts in 2026. Financial terms include up to $100M in upfront/near-term cash, up to 7.0M Zenas shares, total deal value exceeding $2B, and tiered royalties up to high‑teens. Zenas also announced a $120M private placement expected to close ~October 9, 2025, which it says funds operations into Q4 2026 (into Q1 2027 assuming a $75M milestone).

Zenas BioPharma (Nasdaq: ZBIO) has secured a funding agreement with Royalty Pharma (Nasdaq: RPRX) for up to $300 million to support the development and commercialization of obexelimab. The agreement includes an initial $75 million payment and three additional $75 million milestone payments tied to Phase 3 trial success, FDA approval for IgG4-RD, and FDA approval for SLE.

Obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, is currently in Phase 3 development for IgG4-Related Disease with results expected by year-end, and Phase 2 trials for Relapsing Multiple Sclerosis and Systemic Lupus Erythematosus. In exchange for funding, Royalty Pharma will receive a 5.5% royalty on worldwide net sales.

[ "Secured up to $300 million in funding for obexelimab development and commercialization", "Initial $75 million payment extends cash runway through Q1 2027", "Multiple near-term catalysts with Phase 3 IgG4-RD results expected year-end 2025", "Potential blockbuster opportunity in IgG4-RD market" ]

Zenas BioPharma (NASDAQ:ZBIO), a clinical-stage biopharmaceutical company focused on autoimmune disease therapies, has announced its participation in three major healthcare investor conferences in September 2025.

The company will present at the Citi's 2025 Biopharma Back to School Conference (September 2), the Cantor Global Healthcare Conference (September 3), and the Morgan Stanley 23rd Annual Global Healthcare Conference (September 10). All presentations will be accessible via webcast on the company's website.

Zenas BioPharma (NASDAQ:ZBIO) has reported its Q2 2025 financial results and provided updates on its clinical programs. The company ended Q2 with $274.9 million in cash and investments, providing runway into Q4 2026.

Key clinical developments include: expected topline results from the Phase 3 INDIGO trial in IgG4-Related Disease by year-end 2025, completed enrollment in the Phase 2 MoonStone trial for Relapsing Multiple Sclerosis with results expected in early Q4 2025, and ongoing enrollment in the Phase 2 SunStone trial for Systemic Lupus Erythematosus with completion expected by year-end 2025.

Financial results show R&D expenses increased to $43.0 million from $33.8 million year-over-year, while G&A expenses rose to $12.1 million from $5.9 million. Net loss widened to $52.2 million compared to $38.0 million in Q2 2024.

Zenas BioPharma (NASDAQ: ZBIO) has granted an inducement stock option to a new employee on June 16, 2025. The grant includes options to purchase 112,000 shares of common stock at an exercise price of $9.97 per share, matching the company's closing stock price on the grant date. The stock option has a ten-year term and follows a four-year vesting schedule, with 25% vesting after one year of employment and the remaining shares vesting in 36 equal monthly installments. This grant was approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and is subject to the employee's continued service with the company.

Zenas BioPharma (Nasdaq: ZBIO), a clinical-stage biopharmaceutical company focused on autoimmune disease therapies, has announced its upcoming participation in the Jefferies Global Healthcare Conference. The company's management will deliver a presentation on Thursday, June 5, 2025, at 1:25 p.m. ET. Interested parties can access both the live webcast and archived replay of the presentation through the "Events and Presentations" section of Zenas BioPharma's website under Investor & Media Relations.

Zenas BioPharma (NASDAQ: ZBIO) reported Q1 2025 financial results and provided updates on its clinical programs. The company's lead drug candidate obexelimab is advancing in multiple trials: Phase 3 INDIGO trial for IgG4-Related Disease (results expected year-end 2025), Phase 2 MoonStone trial for Relapsing Multiple Sclerosis (results expected Q4 2025), and Phase 2 SunStone trial for Systemic Lupus Erythematosus (completion by year-end 2025, results mid-2026). The company strengthened its leadership with two key appointments and reported $314.2 million in cash and investments as of March 31, 2025, providing runway into Q4 2026. Q1 financial results showed $10.0 million in license revenue from a deal with Zai Lab, while R&D expenses increased to $34.9 million and net loss was $33.6 million.